ClinicalTrials.gg
CompletedNCT02224456Updated Feb 14, 2022Results posted

Efficacy and Safety Study of Tenofovir Disoproxil Fumarate (TDF) in Chinese Chronic Hepatitis B (CHB) Subjects With Advanced Fibrosis & Compensated Cirrhosis

A Phase 4 interventional study of Tenofovir disoproxil fumarate in Hepatitis B, Chronic, sponsored by GlaxoSmithKline. Completed at 19 sites in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2022-02-14.

Sponsored by GlaxoSmithKline · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
197
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing tenofovir in Hepatitis B, Chronic — none open to participants now, 1 under way, 1 of them phase 3. Tenofovir · Hepatitis B, Chronic.

Enrollment
14th of 50
197 · median 117
Started
2015
with 6 others
Phase 4
22 of 50
none open now
Registered
33rd of 50
by date
Lead sponsor
7 of 50
GlaxoSmithKline

Among the 50 studies testing tenofovir in Hepatitis B, Chronic, this one is the 14th largest by enrollment, is one of 7 that started in 2015, is one of 22 in phase 4, and was the 33rd registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

None of the 50 studies testing tenofovir in Hepatitis B, Chronic is open now. The open studies under Hepatitis B, Chronic, anywhere →

About tenofovir

Tenofovir: first FDA approval 2001 (VIREAD), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 50 studies testing tenofovir in Hepatitis B, Chronic as a file.
02

Study summary

Chronic Hepatitis B infection (CHB) is known as the most frequently identified cause of liver disease that predisposes patients to the development of hepatocellular carcinoma (HCC). Active hepatitis B virus (HBV) replication is the key driver of liver injury and disease progression. Majority of Chinese patients are infected with genotype B and C HBV, which is different from Caucasian counterparts. This prospective multi-center cohort open-label study is designed to investigate the long-term effect of TDF on prevention of HCC and disease progression as well as to evaluate the efficacy and safety of long-term TDF in Chinese CHB subjects with advanced liver diseases. The study will enrol 240 subjects.

03

Conditions studied

  • Hepatitis B, Chronic

Keywords

  • Tenofovir disoproxil fumarate
  • hepatocellular carcinoma
  • chronic hepatitis B
  • Cirrhosis
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-60 years(inclusive);
  • Presence of in serum at screening and for at least 6 months before screening assessment;
  • Serum HBV DNA>=2000 IU/mL if HBeAg positive at screening (with or without elevation); or serum HBV DNA>=200IU/mL if HBeAg negative at screening (with or without ALT elevation);
  • Clinically diagnosed as advanced fibrosis or compensated cirrhosis defined as both of following : liver stiffness measure (LSM) >12.4 kiloPascals (kpa) (ALT> [ULN]) or LSM>9.0 kpa (ALT\<=ULN); One of following: Liver showing advanced fibrosis or cirrhosis (Ishak score >=4, within the previous 6 months before screening and provided that no treatment likely to improve liver histology has been taken since). The slides must be available for review by an independent histopathologist; Endoscopy-proven gastroesophageal or gastric varices, non-cirrhotic portal hypertension excluded; Abdominal ultrasound or CT found changes indicating cirrhosis, irregular liver surface or nodularity, with/without splenomegaly (depth of spleen>4.0cm or spleen length>13cm); Blood \<100 x10\^9/L (and other causes of thrombocytopenia excluded);
  • Ability to give written ;
  • A female is eligible to enter and participate in this study if she is of: non- (i.e., physiologically incapable of becoming pregnant, including any female who is ), or Child-bearing potential, has a negative urine pregnancy test at screening, and agrees to one of the following methods for avoidance of pregnancy during the period of the study and until 30 days after last dose of study medication: Oral , either combined or progestogen alone; Injectable progestogen; Implants of levonorgestrel; Oestrogenic vaginal ring; Percutaneous contraceptive patches; Intrauterine device (IUD) or intrauterine system (IUS) showing that the expected failure rate is less than 1% per year as stated in the IUD or IUS product label; Has a male partner who is sterilised; Double barrier method: condom and an occlusive cap (diaphragm orcervical/vault caps) with a vaginal spermicidal agent (foam/gel/film /cream/suppository).
  • Agreement not to participate in any other trials or to undertake other HBV systemic antiviral or interferon (IFN) regimens during participation in this study.

Exclusion criteria

Exclusion Criteria:

  • Hepatocellular carcinoma as evidenced by one of the following: Suspicious foci on ultrasound or radiological examination; Normal ultrasound serum alpha-fetoprotein >50 nanograms (ng)/mL at screening.
  • Serum >10 times at screening or history of acute exacerbation leading to transient decompensation;
  • Documented co-infection with hepatitis A (HAV), (HCV), hepatitis delta virus (HDV), hepatitis E virus (HEV) or (HIV). For HCV co-infection, subjects who are anti-HCV positive and in whom HCV ribonucleic acid (RNA) is undetectable are considered to be not eligible for enrolment.
  • Evidence of active liver disease due to hepatitis (antinuclear antibody (ANA) titre >1:160).
  • Decompensated liver disease as indicated by any of the following: serum >1.5 xULN activity \<60% or International normalized ratio (INR)>1.5; serum albumin \<32 grams per liter (g/L); history of previous clinical hepatic decompensation (e.g., ascites, variceal bleeding, or encephalopathy);
  • Planned for liver transplantation or previous liver transplantation;
  • less than 70 mL/minute (min);
  • \<10 g/deciliter (dL), white blood cell (WBC) count \<1.5 x 10\^9/liter (L), \<=50 x 10\^9/L;
  • Any serious or active medical or psychiatric illnesses other than which, in the opinion of the Investigator, would interfere with subject treatment, assessment or compliance with the protocol. This would include any uncontrolled renal, cardiac, pulmonary, vascular, neurogenic, digestive, metabolic (diabetes, thyroid disorders, adrenal disease), immunodeficiency disorders, pathological fractures or cancer;
  • Active alcohol or drug abuse or history of alcohol or drug abuse considered by the Investigator to be sufficient to hinder compliance with treatment, participation in the study or interpretation of results;
  • A female who is breastfeeding or plan to breastfeed;
  • Use of therapy, immunomodulatory therapy (including IFN or thymosin alpha), systemic cytotoxic agents, chronic antiviral agents including Chinese herbal medicines known to have activity against HBV (e.g., lamivudine (LAM), adefovir, entecavir (ETV), telbivudine (LdT) or hepatitis B immunoglobulin (HBIg)) within the previous 6 months prior to screening into this study;
  • Have ever received TDF or any medicinal products containing the above mentioned antiviral agents or any investigative anti-HBV treatments (e.g., emtricitabine (FTC), (2R,4R)-4-(2,6-Diaminopurin-9-yl)-1,3-dioxolan-2-yl]methanol (DAPD) and 1-(2-fluoro-5-methyl-beta, Larabinofuranosyl) uracil (L-FMAU));
  • History of to nucleoside and/or nucleotide analogues and/or any component of study medication;
  • Therapy with nephrotoxic drugs (e.g., aminoglycosides, amphotercin B, vancomycin, cidofovir, foscarnet, cis-platinum, pentamidine etc.) or competitors of renal excretion (e.g., probenecid) within 2 months prior to study screening or the expectation that subject will receive any of these during the course of the study;
  • Inability to comply with study requirements as determined by the study Investigator
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
197 participants (actual)

Study arms

  • Experimental
    Tenofovir

    Subjects will receive TDF 300 milligrams (mg) tablet once daily for 240 weeks in the study. Subjects who receive add-on rescue treatment may take LAM 100 mg, ETV 0.5 mg or LdT 600 mg per day upon investigator's decision in addition to TDF tablet.

    Drug: Tenofovir disoproxil fumarate

Interventions

  • White, almond-shaped, film-coated tablet containing 300 mg of TDF, debossed with "GILEAD" and "4331" on one side of the tablet.

06

What researchers measure

Primary outcomes

  1. Incidence Rate of Newly Diagnosed Hepatocellular Carcinoma (HCC) at Week 240

    The newly diagnosed HCC was defined as HCC cases from Week 24 to Week 240 and the participants were required to meet one of the following criteria: without HCC before Week 24; a histological diagnosis of HCC (i.e. by biopsy or at post-mortem); participants with nodules \>2 centimeter (cm), identification of typical HCC characteristics (hyper-vascular in the arterial phase with washout in the portal venous or delayed phases) by 4-phase multi-detector computed tomography (CT) scan or dynamic contrast-enhanced magnetic resonance imaging (MRI); participants with nodules \>1 cm, identification of typical HCC characteristics by both techniques (4-phase multi-detector CT and dynamic contrast-enhanced MRI).

    Time frame: Week 240

  2. Percentage of Participants With Disease Progression at Week 240

    Disease progression was defined as the first occurrence of any one of the following criteria: 1) an increase in Childs-Pugh score of 2 or more points from Baseline; 2) an increase in Childs-Pugh score of 2 or more points, solely based on laboratory parameters (i.e. bilirubin, prothrombin time and/or albumin) confirmed between two consecutive visits at least one month apart; 3) spontaneous bacterial peritonitis (with proven sepsis); 4) renal insufficiency; 5) bleeding gastric/esophageal varices; 6) hepatocellular carcinoma; 7)liver-related death.

    Time frame: Week 240

Secondary outcomes

  1. Number of Participants With Newly Diagnosed Hepatocellular Carcinoma (HCC) at Week 48, Week 96, Week 144 and Week 192

    The newly diagnosed HCC was defined as HCC cases from Week 24 to Week 240 and the participants were required to meet one of the following criteria: without HCC before Week 24; a histological diagnosis of HCC (i.e. by biopsy or at post-mortem); participants with nodules \>2 centimeter (cm), identification of typical HCC characteristics (hyper-vascular in the arterial phase with washout in the portal venous or delayed phases) by 4-phase multi-detector computed tomography (CT) scan or dynamic contrast-enhanced magnetic resonance imaging (MRI); participants with nodules \>1 cm, identification of typical HCC characteristics by both techniques (4-phase multi-detector CT and dynamic contrast-enhanced MRI).

    Time frame: Week 48, Week 96, Week 144 and Week 192

  2. Percentage of Participants With Newly Diagnosed Hepatocellular Carcinoma (HCC) at Week 48, Week 96, Week 144, Week 192 and Week 240

    The newly diagnosed HCC was defined as HCC cases from Week 24 to Week 240 and the participants were required to meet one of the following criteria: without HCC before Week 24; a histological diagnosis of HCC (i.e. by biopsy or at post-mortem); participants with nodules \>2 centimeter (cm), identification of typical HCC characteristics (hyper-vascular in the arterial phase with washout in the portal venous or delayed phases) by 4-phase multi-detector computed tomography (CT) scan or dynamic contrast-enhanced magnetic resonance imaging (MRI); participants with nodules \>1 cm, identification of typical HCC characteristics by both techniques (4-phase multi-detector CT and dynamic contrast-enhanced MRI).The cumulative percentage of participants with newly diagnosed Hepatocellular Carcinoma has been presented along with 95% confidence interval (CI) (Wald method).

    Time frame: Week 48, Week 96, Week 144, Week 192 and Week 240

  3. Percentage of Participants With Disease Progression at Week 48, Week 96, Week 144, Week 192 and Week 240

    Disease progression was defined as the first occurrence of any one of the following criteria: 1) an increase in Childs-Pugh score of 2 or more points from Baseline; 2) an increase in Childs-Pugh score of 2 or more points, solely based on laboratory parameters (i.e. bilirubin, prothrombin time and/or albumin) confirmed between two consecutive visits at least one month apart; 3) spontaneous bacterial peritonitis (with proven sepsis); 4) renal insufficiency; 5) bleeding gastric/oesophageal varices; 6) hepatocellular carcinoma; 7) liver-related death. The cumulative percentage of participants with disease progression has been presented along with 95% CI (Wald method).

    Time frame: Week 48, Week 96, Week 144, Week 192 and Week 240

  4. Mean Change From Baseline in Liver Stiffness Measure at Week 48, Week 96, Week 144, Week 192 and Week 240

    Liver stiffness measure was obtained by a non-invasive transient elastography using FibroScan. Baseline is defined as the last assessment (Day 0) before administration of the study drug. Change from Baseline is defined as post-dose visit value minus Baseline value

    Time frame: Baseline (Day 0), Week 48, Week 96, Week 144, Week 192 and Week 240

  5. Percentage of Participants With Serum Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) <20 International Units Per Milliliter (IU/mL) at Weeks 48, 96, 144, 192 and 240

    Serum samples were collected for the analysis of HBV DNA levels using Roche Cobas Taqman HBV test. Confidence interval was calculated by normal approximation and continuity correction method.

    Time frame: Week 48, Week 96, Week 144, Week 192 and Week 240

  6. Change From Baseline in Logarithm to the Base 10 (Log 10) Serum HBV DNA

    Serum samples were collected for the analysis of HBV DNA levels. Baseline is defined as the last assessment (Day 0) before administration of the study drug. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

    Time frame: Baseline (Day 0) and Week 48, Week 96, Week 144, Week 192 and Week 240

  7. Percentage of Participants With Alanine Aminotransferase (ALT) Normalization at Week 48, Week 96, Week 144, Week 192 and Week 240 in Participants Who Had Abnormal ALT at Baseline

    Blood samples were collected for evaluation of ALT at indicated time points. ALT normalization is defined as ALT outside the normal range at Baseline and within the normal range at Week 48, Week 96, Week 144, Week 192 and Week 240. Normal range of ALT is 7 to 56 International Units per liter. Percentage of participants with ALT normalization at Weeks 48, 96, 144, 192 and 240 in participants who had abnormal ALT at Baseline (Day 0) have been presented. Confidence interval was calculated using normal approximation and continuity correction method.

    Time frame: Week 48, Week 96, Week 144, Week 192 and Week 240

  8. Percentage of Hepatitis B e Antigen (HBeAg) Positive Participants Achieving HBeAg Loss, HBeAg Seroconversion at Week 48, Week 96, Week 144, Week 192 and Week 240.

    Serological response was assessed at Week 48, Week 96, Week 144, Week 192 and Week 240 in participants with Positive HBeAg at Baseline (Day 0). It was presented as HBeAg Loss and HBeAg Seroconversion. HBeAg Loss was defined as HBeAg changed to be negative. HBeAg seroconversion was defined as HBeAg changed to negative and HBeAb was positive. Confidence interval was calculated using normal approximation and continuity correction method.

    Time frame: Week 48, Week 96, Week 144, Week 192 and Week 240

  9. Percentage of HBeAg Negative Participants Achieving HBsAg Loss and HBsAg Seroconversion at Week 48, Week 96, Week 144, Week 192 and Week 240

    Serological response was assessed at Week 48, Week 96, Week 144, Week 192 and Week 240 in participants with negative HBeAg at Baseline (Day 0). HBsAg Loss was defined as HBsAg changed to be negative. HBsAg seroconversion was defined as HBsAg changed to negative and HBsAb was positive.

    Time frame: Week 48, Week 96, Week 144, Week 192 and Week 240

  10. Percentage of Participants Who Experienced Viral Breakthrough

    Viral breakthrough was defined as \>=1 log10 increase in HBV DNA from nadir determined by two sequential HBV DNA measurements. Percentage of Participants who experienced viral breakthrough at Week 48, Week 96, Week 144, Week 192 and Week 240 is presented.

    Time frame: Week 48, Week 96, Week 144, Week 192 and Week 240

  11. Percentage of Participants With Histological Improvement at Week 216

    The Knodell scoring system, also called the Histologic Activity Index (HAI), classifies liver biopsy specimens according to scores into 4 categories of histologic features: (I) Periportal or periseptal interface hepatitis (piecemeal necrosis) (scores from 0, 1, 2, 3, 4 or 10); (II) Confluent necrosis (scores from 0, 1, 3, 4, 5, 6 or 10); (III) Focal (spotty) lytic necrosis, apoptosis and focal inflammation (scores from 0, 1, 2, 3, 4 or 10); (IV) Portal inflammation (scores from 0, 1, 2, 3, 4 or 10). Histological improvement is considered as a reduction of two or more points in the Knodell necroinflammatory score with no increase in fibrosis.

    Time frame: Week 216

  12. Percentage of Participants With Cirrhosis Reversal at Week 216

    Cirrhosis reversal was defined as a reduction of one or more points in the Ishak score with no evidence of cirrhosis. The Ishak liver fibrosis score ranges from 0 indicating no fibrosis to 6 indicating cirrhosis.

    Time frame: Week 216

  13. Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs and Non-serious TEAEs

    An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAE is defined as AE that occurred on or after the first dose date of study drug. SAE is any untoward medical occurrence that results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, is a congenital anomaly/birth defect and other situations according to medical or scientific judgement or events possible drug-induced liver injury with hyperbilirubinemia.

    Time frame: Up to Week 240

  14. Change From Baseline in Hematology Parameters: White Blood Cells (WBC), Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets

    Blood samples were collected to analyze the hematology parameters: basophils, eosinophils, WBC, lymphocytes, monocytes, neutrophils and platelets. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

    Time frame: Baseline (Day 0) and at Week 48, Week 96, Week 144, Week 192 and Week 240

  15. Change From Baseline in Hemoglobin (Hb)

    Blood samples were collected to analyze Hb values. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

    Time frame: Baseline (Day 0) and at Week 48, Week 96, Week 144, Week 192 and Week 240

  16. Change From Baseline in Red Blood Cells (RBC)

    Blood samples were collected to analyze RBC values. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

    Time frame: Baseline (Day 0) and at Week 48, Week 96, Week 144, Week 192 and Week 240

  17. Change From Baseline in Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-Glutamyltransferase (GGT), Creatinine Phosphokinase (CK), Lactose Dehydrogenase (LDH)

    Blood samples were collected to analyze the chemistry parameters: ALT, ALP, AST, GGT, CK, LDH. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

    Time frame: Baseline (Day 0) and at Week 48, Week 96, Week 144, Week 192 and Week 240

  18. Change From Baseline in Chemistry Parameters: Total Bilirubin, Direct Bilirubin, Serum Creatinine

    Blood samples were collected to analyze the chemistry parameters: total billirubin,direct bilirubin and serum creatinine. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

    Time frame: Baseline (Day 0) and at Week 48, Week 96, Week 144, Week 192 and Week 240

  19. Change From Baseline in Chemistry Parameters: Albumin and Total Protein

    Blood samples were collected to analyze the chemistry parameters: albumin and total protein. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

    Time frame: Baseline (Day 0) and at Week 48, Week 96, Week 144, Week 192 and Week 240

  20. Change From Baseline in Chemistry Parameter: Blood Urea Nitrogen (BUN), Potassium, Sodium, Chloridion, Phosphorus, Calcium and Fasting Blood Glucose

    Blood samples were collected to analyze the chemistry parameters: BUN, potassium, sodium, chloridion, phosphorus,calcium and fasting blood glucose. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

    Time frame: Baseline (Day 0) and at Week 48, Week 96, Week 144, Week 192 and Week 240

  21. Change From Baseline in Chemistry Parameters: Creatinine Clearance Rate

    Blood samples were collected to analyze the chemistry parameters: creatinine clearance rate. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

    Time frame: Baseline (Day 0) and at Week 48, Week 96, Week 144, Week 192 and Week 240

  22. Change From Baseline in Chemistry Parameters: Estimated Glomerular Filtration Rate (eGFR)

    Blood samples were collected to analyze the chemistry parameters: eGFR. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

    Time frame: Baseline (Day 0) and at Week 48, Week 96, Week 144, Week 192 and Week 240

07

Results

Posted Feb 14, 2022

Participant flow

This study was conducted to evaluate the efficacy and safety of 300 milligram (mg) Tenofovir Disoproxil Fumarate (TDF) therapy in Chinese chronic hepatitis B (CHB) participants with advanced fibrosis and compensated cirrhosis

Participant flow — Overall Study
MilestoneTenofovir Disoproxil Fumarate 300 mg
Started197
Completed161
Not completed36
Withdrew: Lack of efficacy1
Withdrew: Lost to follow-up15
Withdrew: Withdrawal by subject9
Withdrew: Physician decision3
Withdrew: Death2
Withdrew: Pregnancy4
Withdrew: Protocol violation1
Withdrew: Treatment interruptions of ≥28 days1

Outcome measures

PrimaryIncidence Rate of Newly Diagnosed Hepatocellular Carcinoma (HCC) at Week 240

The newly diagnosed HCC was defined as HCC cases from Week 24 to Week 240 and the participants were required to meet one of the following criteria: without HCC before Week 24; a histological diagnosis of HCC (i.e. by biopsy or at post-mortem); participants with nodules \>2 centimeter (cm), identification of typical HCC characteristics (hyper-vascular in the arterial phase with washout in the portal venous or delayed phases) by 4-phase multi-detector computed tomography (CT) scan or dynamic contrast-enhanced magnetic resonance imaging (MRI); participants with nodules \>1 cm, identification of typical HCC characteristics by both techniques (4-phase multi-detector CT and dynamic contrast-enhanced MRI).

Time frame:
Week 240
Reported as:
Number · Events per person-year
Incidence Rate of Newly Diagnosed Hepatocellular Carcinoma (HCC) at Week 240
Events per person-yearTenofovir Disoproxil Fumarate 300 mg
Incidence Rate of Newly Diagnosed Hepatocellular Carcinoma (HCC) at Week 2406.045
PrimaryPercentage of Participants With Disease Progression at Week 240

Disease progression was defined as the first occurrence of any one of the following criteria: 1) an increase in Childs-Pugh score of 2 or more points from Baseline; 2) an increase in Childs-Pugh score of 2 or more points, solely based on laboratory parameters (i.e. bilirubin, prothrombin time and/or albumin) confirmed between two consecutive visits at least one month apart; 3) spontaneous bacterial peritonitis (with proven sepsis); 4) renal insufficiency; 5) bleeding gastric/esophageal varices; 6) hepatocellular carcinoma; 7)liver-related death.

Time frame:
Week 240
Reported as:
Number · Percentage of participants
Percentage of Participants With Disease Progression at Week 240
Percentage of participantsTenofovir Disoproxil Fumarate 300 mg
Percentage of Participants With Disease Progression at Week 2407.2
SecondaryNumber of Participants With Newly Diagnosed Hepatocellular Carcinoma (HCC) at Week 48, Week 96, Week 144 and Week 192

The newly diagnosed HCC was defined as HCC cases from Week 24 to Week 240 and the participants were required to meet one of the following criteria: without HCC before Week 24; a histological diagnosis of HCC (i.e. by biopsy or at post-mortem); participants with nodules \>2 centimeter (cm), identification of typical HCC characteristics (hyper-vascular in the arterial phase with washout in the portal venous or delayed phases) by 4-phase multi-detector computed tomography (CT) scan or dynamic contrast-enhanced magnetic resonance imaging (MRI); participants with nodules \>1 cm, identification of typical HCC characteristics by both techniques (4-phase multi-detector CT and dynamic contrast-enhanced MRI).

Time frame:
Week 48, Week 96, Week 144 and Week 192
Reported as:
Count of participants · Participants
Number of Participants With Newly Diagnosed Hepatocellular Carcinoma (HCC) at Week 48, Week 96, Week 144 and Week 192
ParticipantsTenofovir Disoproxil Fumarate 300 mg
Week 480
Week 960
Week 1444
Week 1929
SecondaryPercentage of Participants With Newly Diagnosed Hepatocellular Carcinoma (HCC) at Week 48, Week 96, Week 144, Week 192 and Week 240

The newly diagnosed HCC was defined as HCC cases from Week 24 to Week 240 and the participants were required to meet one of the following criteria: without HCC before Week 24; a histological diagnosis of HCC (i.e. by biopsy or at post-mortem); participants with nodules \>2 centimeter (cm), identification of typical HCC characteristics (hyper-vascular in the arterial phase with washout in the portal venous or delayed phases) by 4-phase multi-detector computed tomography (CT) scan or dynamic contrast-enhanced magnetic resonance imaging (MRI); participants with nodules \>1 cm, identification of typical HCC characteristics by both techniques (4-phase multi-detector CT and dynamic contrast-enhanced MRI).The cumulative percentage of participants with newly diagnosed Hepatocellular Carcinoma has been presented along with 95% confidence interval (CI) (Wald method).

Time frame:
Week 48, Week 96, Week 144, Week 192 and Week 240
Reported as:
Number · Percentage of participants
Percentage of Participants With Newly Diagnosed Hepatocellular Carcinoma (HCC) at Week 48, Week 96, Week 144, Week 192 and Week 240
Percentage of participantsTenofovir Disoproxil Fumarate 300 mg
Week 480 (NA to NA)
Week 960 (NA to NA)
Week 1442.1 (0.0 to 4.3)
Week 1924.6 (1.4 to 7.8)
Week 2405.6 (2.1 to 9.1)
SecondaryPercentage of Participants With Disease Progression at Week 48, Week 96, Week 144, Week 192 and Week 240

Disease progression was defined as the first occurrence of any one of the following criteria: 1) an increase in Childs-Pugh score of 2 or more points from Baseline; 2) an increase in Childs-Pugh score of 2 or more points, solely based on laboratory parameters (i.e. bilirubin, prothrombin time and/or albumin) confirmed between two consecutive visits at least one month apart; 3) spontaneous bacterial peritonitis (with proven sepsis); 4) renal insufficiency; 5) bleeding gastric/oesophageal varices; 6) hepatocellular carcinoma; 7) liver-related death. The cumulative percentage of participants with disease progression has been presented along with 95% CI (Wald method).

Time frame:
Week 48, Week 96, Week 144, Week 192 and Week 240
Reported as:
Number · Percentage of participants
Percentage of Participants With Disease Progression at Week 48, Week 96, Week 144, Week 192 and Week 240
Percentage of participantsTenofovir Disoproxil Fumarate 300 mg
Week 482.1 (0.0 to 4.3)
Week 962.6 (0.1 to 5.0)
Week 1444.1 (1.1 to 7.1)
Week 1927.2 (3.3 to 11.1)
Week 2407.2 (3.3 to 11.1)
SecondaryMean Change From Baseline in Liver Stiffness Measure at Week 48, Week 96, Week 144, Week 192 and Week 240

Liver stiffness measure was obtained by a non-invasive transient elastography using FibroScan. Baseline is defined as the last assessment (Day 0) before administration of the study drug. Change from Baseline is defined as post-dose visit value minus Baseline value

Time frame:
Baseline (Day 0), Week 48, Week 96, Week 144, Week 192 and Week 240
Reported as:
Mean · Kilopascals
Mean Change From Baseline in Liver Stiffness Measure at Week 48, Week 96, Week 144, Week 192 and Week 240
KilopascalsTenofovir Disoproxil Fumarate 300 mg
Week 48, n=182-3.3 ± 4.84
Week 96, n= 176-4.7 ± 5.60
Week 144, n= 175-5.1 ± 5.85
Week 192, n=167-5.1 ± 7.82
Week 240, n= 131-6.2 ± 5.55
SecondaryPercentage of Participants With Serum Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) <20 International Units Per Milliliter (IU/mL) at Weeks 48, 96, 144, 192 and 240

Serum samples were collected for the analysis of HBV DNA levels using Roche Cobas Taqman HBV test. Confidence interval was calculated by normal approximation and continuity correction method.

Time frame:
Week 48, Week 96, Week 144, Week 192 and Week 240
Reported as:
Number · Percentage of participants
Percentage of Participants With Serum Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) <20 International Units Per Milliliter (IU/mL) at Weeks 48, 96, 144, 192 and 240
Percentage of participantsTenofovir Disoproxil Fumarate 300 mg
Week 48, n=19181.2 (75.3 to 87.0)
Week 96, n=18888.8 (84.1 to 93.6)
Week 144, n=18594.1 (90.4 to 97.7)
Week 192, n=17497.7 (95.2 to 100.0)
Week 240, n=16099.4 (97.8 to 100.0)
SecondaryChange From Baseline in Logarithm to the Base 10 (Log 10) Serum HBV DNA

Serum samples were collected for the analysis of HBV DNA levels. Baseline is defined as the last assessment (Day 0) before administration of the study drug. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

Time frame:
Baseline (Day 0) and Week 48, Week 96, Week 144, Week 192 and Week 240
Reported as:
Mean · Log 10 (IU/mL)
Change From Baseline in Logarithm to the Base 10 (Log 10) Serum HBV DNA
Log 10 (IU/mL)Tenofovir Disoproxil Fumarate 300 mg
Week 48, n=191-4.2 ± 1.40
Week 96, n=188-4.3 ± 1.44
Week 144, n=185-4.3 ± 1.48
Week 192, n=174-4.2 ± 1.50
Week 240, n=160-4.3 ± 1.46
SecondaryPercentage of Participants With Alanine Aminotransferase (ALT) Normalization at Week 48, Week 96, Week 144, Week 192 and Week 240 in Participants Who Had Abnormal ALT at Baseline

Blood samples were collected for evaluation of ALT at indicated time points. ALT normalization is defined as ALT outside the normal range at Baseline and within the normal range at Week 48, Week 96, Week 144, Week 192 and Week 240. Normal range of ALT is 7 to 56 International Units per liter. Percentage of participants with ALT normalization at Weeks 48, 96, 144, 192 and 240 in participants who had abnormal ALT at Baseline (Day 0) have been presented. Confidence interval was calculated using normal approximation and continuity correction method.

Time frame:
Week 48, Week 96, Week 144, Week 192 and Week 240
Reported as:
Number · Percentage of participants
Percentage of Participants With Alanine Aminotransferase (ALT) Normalization at Week 48, Week 96, Week 144, Week 192 and Week 240 in Participants Who Had Abnormal ALT at Baseline
Percentage of participantsTenofovir Disoproxil Fumarate 300 mg
Week 48, n=9763.9 (53.8 to 74.0)
Week 96, n= 9766.0 (56.0 to 75.9)
Week 144, n=9670.8 (61.2 to 80.4)
Week 192, n=9382.8 (74.6 to 91.0)
Week 240, n=8782.8 (74.2 to 91.3)
SecondaryPercentage of Hepatitis B e Antigen (HBeAg) Positive Participants Achieving HBeAg Loss, HBeAg Seroconversion at Week 48, Week 96, Week 144, Week 192 and Week 240.

Serological response was assessed at Week 48, Week 96, Week 144, Week 192 and Week 240 in participants with Positive HBeAg at Baseline (Day 0). It was presented as HBeAg Loss and HBeAg Seroconversion. HBeAg Loss was defined as HBeAg changed to be negative. HBeAg seroconversion was defined as HBeAg changed to negative and HBeAb was positive. Confidence interval was calculated using normal approximation and continuity correction method.

Time frame:
Week 48, Week 96, Week 144, Week 192 and Week 240
Reported as:
Number · Percentage of participants
Percentage of Hepatitis B e Antigen (HBeAg) Positive Participants Achieving HBeAg Loss, HBeAg Seroconversion at Week 48, Week 96, Week 144, Week 192 and Week 240.
Percentage of participantsTenofovir Disoproxil Fumarate 300 mg
Week 48, HBeAg Loss, n=9418.1 (9.8 to 26.4)
Week 48, HBeAg Seroconversion, n=949.6 (3.1 to 16.1)
Week 96, HBeAg , n=9433.0 (22.9 to 43.0)
Week 96, HBeAg Seroconversion, n=9414.9 (7.2 to 22.6)
Week 144, HBeAg Loss, n=9035.6 (24.5 to 45.1)
Week 144, HBeAg Seroconversion, n=9014.4 (6.5 to 21.8)
Week 192, HBeAg Loss, n=9047.8 (36.4 to 58.1)
Week 192, HBeAg Seroconversion, n=9016.7 (8.3 to 24.7)
Week 240, HBeAg Loss, n=8251.2 (38.7 to 61.3)
Week 240, HBeAg Seroconversion, n=8223.2 (13.1 to 32.2)
SecondaryPercentage of HBeAg Negative Participants Achieving HBsAg Loss and HBsAg Seroconversion at Week 48, Week 96, Week 144, Week 192 and Week 240

Serological response was assessed at Week 48, Week 96, Week 144, Week 192 and Week 240 in participants with negative HBeAg at Baseline (Day 0). HBsAg Loss was defined as HBsAg changed to be negative. HBsAg seroconversion was defined as HBsAg changed to negative and HBsAb was positive.

Time frame:
Week 48, Week 96, Week 144, Week 192 and Week 240
Reported as:
Number · Percentage of Participants
Percentage of HBeAg Negative Participants Achieving HBsAg Loss and HBsAg Seroconversion at Week 48, Week 96, Week 144, Week 192 and Week 240
Percentage of ParticipantsTenofovir Disoproxil Fumarate 300 mg
Week 48, HBsAg Loss, n=971.0 (0.0 to 3.6)
Week 48, HBsAg Seroconversion, n=971.0 (0.0 to 3.6)
Week 96, HBsAg , n=930 (0.0 to 0.5)
Week 96, HBsAg Seroconversion, n=930 (0.0 to 0.5)
Week 144, HBsAg Loss, n=933.2 (0.0 to 7.4)
Week 144, HBsAg Seroconversion, n=930 (0.0 to 0.5)
Week 192, HBsAg Loss, n=894.5 (0.0 to 9.4)
Week 192, HBsAg Seroconversion, n=892.2 (0.0 to 5.9)
Week 240, HBsAg Loss, n=775.2 (0.0 to 10.8)
Week 240, HBsAg Seroconversion, n=771.3 (0.0 to 4.5)
SecondaryPercentage of Participants Who Experienced Viral Breakthrough

Viral breakthrough was defined as \>=1 log10 increase in HBV DNA from nadir determined by two sequential HBV DNA measurements. Percentage of Participants who experienced viral breakthrough at Week 48, Week 96, Week 144, Week 192 and Week 240 is presented.

Time frame:
Week 48, Week 96, Week 144, Week 192 and Week 240
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experienced Viral Breakthrough
Percentage of ParticipantsTenofovir Disoproxil Fumarate 300 mg
Week 48, n=1950 (NA to NA)
Week 96, n=1950 (NA to NA)
Week 144, n=1850.5 (0.0 to 1.9)
Week 192, n=1801.1 (0.0 to 2.9)
Week 240, n=1610.6 (0.0 to 2.1)
SecondaryPercentage of Participants With Histological Improvement at Week 216

The Knodell scoring system, also called the Histologic Activity Index (HAI), classifies liver biopsy specimens according to scores into 4 categories of histologic features: (I) Periportal or periseptal interface hepatitis (piecemeal necrosis) (scores from 0, 1, 2, 3, 4 or 10); (II) Confluent necrosis (scores from 0, 1, 3, 4, 5, 6 or 10); (III) Focal (spotty) lytic necrosis, apoptosis and focal inflammation (scores from 0, 1, 2, 3, 4 or 10); (IV) Portal inflammation (scores from 0, 1, 2, 3, 4 or 10). Histological improvement is considered as a reduction of two or more points in the Knodell necroinflammatory score with no increase in fibrosis.

Time frame:
Week 216
Reported as:
Number · Percentage of participants
Percentage of Participants With Histological Improvement at Week 216
Percentage of participantsTenofovir Disoproxil Fumarate 300 mg
Percentage of Participants With Histological Improvement at Week 21645.2 (26.0 to 64.3)
SecondaryPercentage of Participants With Cirrhosis Reversal at Week 216

Cirrhosis reversal was defined as a reduction of one or more points in the Ishak score with no evidence of cirrhosis. The Ishak liver fibrosis score ranges from 0 indicating no fibrosis to 6 indicating cirrhosis.

Time frame:
Week 216
Reported as:
Number · Percentage of participants
Percentage of Participants With Cirrhosis Reversal at Week 216
Percentage of participantsTenofovir Disoproxil Fumarate 300 mg
Percentage of Participants With Cirrhosis Reversal at Week 21641.9 (23.0 to 60.9)
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs and Non-serious TEAEs

An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAE is defined as AE that occurred on or after the first dose date of study drug. SAE is any untoward medical occurrence that results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, is a congenital anomaly/birth defect and other situations according to medical or scientific judgement or events possible drug-induced liver injury with hyperbilirubinemia.

Time frame:
Up to Week 240
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs and Non-serious TEAEs
ParticipantsTenofovir Disoproxil Fumarate 300 mg
Any TEAEs139
Serious TEAE34
Non-serious TEAE129
SecondaryChange From Baseline in Hematology Parameters: White Blood Cells (WBC), Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets

Blood samples were collected to analyze the hematology parameters: basophils, eosinophils, WBC, lymphocytes, monocytes, neutrophils and platelets. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

Time frame:
Baseline (Day 0) and at Week 48, Week 96, Week 144, Week 192 and Week 240
Reported as:
Mean · 10^9 cells per liter
Change From Baseline in Hematology Parameters: White Blood Cells (WBC), Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets
10^9 cells per literTenofovir Disoproxil Fumarate 300 mg
Week 48, WBC, n=1910.02 ± 1.264
Week 96, WBC, n=1880.09 ± 1.380
Week 144, WBC, n=185-0.12 ± 1.378
Week 192, WBC, n=1790.12 ± 1.412
Week 240, WBC, n=1600.06 ± 1.434
Week 48, Neutrophils, n=1910.08 ± 1.051
Week 96, Neutrophils, n=1880.21 ± 1.184
Week 144, Neutrophils, n=1850.07 ± 1.162
Week 192, Neutrophils, n=1790.26 ± 1.197
Week 240, Neutrophils, n=1600.28 ± 1.194
Week 48, Lymphocytes, n=1910.00 ± 0.438
Week 96, Lymphocytes, n=188-0.06 ± 0.511
Week 144, Lymphocytes, n=185-0.13 ± 0.422
Week 192, Lymphocytes, n=179-0.10 ± 0.442
Week 240, Lymphocytes, n=160-0.15 ± 0.483
Week 48, Monocytes, n=191-0.032 ± 0.1056
Week 96, Monocytes, n=188-0.033 ± 0.1113
Week 144, Monocytes, n=185-0.035 ± 0.1244
Week 192, Monocytes, n=179-0.025 ± 0.1162
Week 240, Monocytes, n=160-0.005 ± 0.1664
Week 48, Eosinophils, n=191-0.02 ± 0.114
Week 96, Eosinophils, n=188-0.02 ± 0.164
Week 144, Eosinophils, n=185-0.04 ± 0.237
Week 192, Eosinophils, n=179-0.03 ± 0.248
Week 240, Eosinophils, n=160-0.03 ± 0.251
Week 48, Basophils, n=1910.00 ± 0.017
Week 96, Basophils, n=1880.00 ± 0.019
Week 144, Basophils, n=1840.01 ± 0.025
Week 192, Basophils, n=1790.01 ± 0.021
Week 240, Basophils, n=1600.01 ± 0.033
Week 48, Platelets, n=1917.8 ± 31.45
Week 96, Platelets, n=18814.1 ± 32.46
Week 144, Platelets, n=18520.6 ± 42.02
Week 192, Platelets, n=17925.7 ± 42.56
Week 240, Platelets, n=16026.6 ± 38.39
SecondaryChange From Baseline in Hemoglobin (Hb)

Blood samples were collected to analyze Hb values. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

Time frame:
Baseline (Day 0) and at Week 48, Week 96, Week 144, Week 192 and Week 240
Reported as:
Mean · Grams per liter
Change From Baseline in Hemoglobin (Hb)
Grams per literTenofovir Disoproxil Fumarate 300 mg
Week 48, n=191-0.6 ± 10.12
Week 96, n=1880.2 ± 11.63
Week 144, n=1850.9 ± 11.26
Week 192, n=179-0.3 ± 12.61
Week 240, n=1601.2 ± 12.71
SecondaryChange From Baseline in Red Blood Cells (RBC)

Blood samples were collected to analyze RBC values. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

Time frame:
Baseline (Day 0) and at Week 48, Week 96, Week 144, Week 192 and Week 240
Reported as:
Mean · Trillion cells per liter
Change From Baseline in Red Blood Cells (RBC)
Trillion cells per literTenofovir Disoproxil Fumarate 300 mg
Week 48, n=1910.11 ± 0.306
Week 96, n=1880.13 ± 0.344
Week 144, n=1850.15 ± 0.340
Week 192, n=1790.10 ± 0.363
Week 240, n=1600.12 ± 0.341
SecondaryChange From Baseline in Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-Glutamyltransferase (GGT), Creatinine Phosphokinase (CK), Lactose Dehydrogenase (LDH)

Blood samples were collected to analyze the chemistry parameters: ALT, ALP, AST, GGT, CK, LDH. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

Time frame:
Baseline (Day 0) and at Week 48, Week 96, Week 144, Week 192 and Week 240
Reported as:
Mean · Units per liter
Change From Baseline in Chemistry Parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP), Aspartate Aminotransferase (AST), Gamma-Glutamyltransferase (GGT), Creatinine Phosphokinase (CK), Lactose Dehydrogenase (LDH)
Units per literTenofovir Disoproxil Fumarate 300 mg
Week 48, ALT, n=190-23.98 ± 59.452
Week 96, ALT, n=187-28.99 ± 56.983
Week 144, ALT, n=185-28.99 ± 56.983
Week 192, ALT, n=178-31.79 ± 57.955
Week 240, ALT, n=158-32.02 ± 63.157
Week 48, AST, n=191-14.69 ± 36.674
Week 96, AST, n=188-17.97 ± 36.057
Week 144, AST, n=184-18.10 ± 36.809
Week 192, AST, n=178-19.82 ± 36.312
Week 240, AST, n=158-20.24 ± 43.908
Week 48, ALP, n=19010.18 ± 20.288
Week 96, ALP, n=1882.60 ± 28.233
Week 144, ALP, n=185-2.20 ± 26.555
Week 192, ALP, n=177-0.94 ± 31.604
Week 240, ALP, n=158-4.68 ± 27.596
Week 48, GGT, n=190-17.88 ± 32.753
Week 96, GGT, n=188-22.20 ± 34.866
Week 144, GGT, n=185-24.69 ± 39.764
Week 192, GGT, n=175-24.07 ± 38.609
Week 240, GGT, n=152-27.26 ± 42.932
Week 48 CK, n=18810.51 ± 103.515
Week 96, CK, n=18516.77 ± 141.961
Week 144, CK, n=1825.96 ± 101.897
Week 192, CK, n=17313.72 ± 106.986
Week 240, CK, n=1562.79 ± 105.349
Week 48, LDH, n=187-10.62 ± 52.851
Week 96, LDH, n=185-10.21 ± 48.112
Week 144, LDH, n=1803.34 ± 73.047
Week 192, LDH, n=172-18.45 ± 87.931
Week 240, LDH, n=15525.79 ± 87.464
SecondaryChange From Baseline in Chemistry Parameters: Total Bilirubin, Direct Bilirubin, Serum Creatinine

Blood samples were collected to analyze the chemistry parameters: total billirubin,direct bilirubin and serum creatinine. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

Time frame:
Baseline (Day 0) and at Week 48, Week 96, Week 144, Week 192 and Week 240
Reported as:
Mean · Micromoles per liter
Change From Baseline in Chemistry Parameters: Total Bilirubin, Direct Bilirubin, Serum Creatinine
Micromoles per literTenofovir Disoproxil Fumarate 300 mg
Week 48, total bilirubin, n=191-1.485 ± 7.1347
Week 96, total bilirubin, n=188-1.823 ± 6.7167
Week 144, total bilirubin, n=185-2.665 ± 7.1281
Week 192, total bilirubin, n=177-2.791 ± 6.9230
Week 240, total bilirubin, n=158-1.772 ± 6.9786
Week 48, direct bilirubin, n=191-0.296 ± 3.1229
Week 96, direct bilirubin, n=188-0.462 ± 3.1875
Week 144, direct bilirubin, n=185-0.713 ± 3.4898
Week 192, direct bilirubin, n=178-0.780 ± 3.5942
Week 240, direct bilirubin, n=157-0.599 ± 3.5608
Week 48, serum creatinine, n=1911.03 ± 7.020
Week 96, serum creatinine, n=1881.10 ± 7.597
Week 144, serum creatinine, n=1840.76 ± 9.122
Week 192, serum creatinine, n=1781.37 ± 8.591
Week 240, serum creatinine, n=1591.35 ± 9.879
SecondaryChange From Baseline in Chemistry Parameters: Albumin and Total Protein

Blood samples were collected to analyze the chemistry parameters: albumin and total protein. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

Time frame:
Baseline (Day 0) and at Week 48, Week 96, Week 144, Week 192 and Week 240
Reported as:
Mean · Grams per liter
Change From Baseline in Chemistry Parameters: Albumin and Total Protein
Grams per literTenofovir Disoproxil Fumarate 300 mg
Week 48, albumin, n=1911.06 ± 3.063
Week 96, albumin, n=1881.23 ± 3.313
Week 144, albumin, n=1851.86 ± 3.675
Week 192, albumin, n=1751.65 ± 3.780
Week 240, albumin, n=1581.81 ± 3.790
Week 48, total protein, n=191-1.01 ± 5.273
Week 96, total protein, n=188-0.21 ± 5.397
Week 144, total protein, n=1850.27 ± 5.065
Week 192, total protein, n=175-0.94 ± 5.175
Week 240, total protein, n=158-1.61 ± 5.829
SecondaryChange From Baseline in Chemistry Parameter: Blood Urea Nitrogen (BUN), Potassium, Sodium, Chloridion, Phosphorus, Calcium and Fasting Blood Glucose

Blood samples were collected to analyze the chemistry parameters: BUN, potassium, sodium, chloridion, phosphorus,calcium and fasting blood glucose. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

Time frame:
Baseline (Day 0) and at Week 48, Week 96, Week 144, Week 192 and Week 240
Reported as:
Mean · Millimoles per liter
Change From Baseline in Chemistry Parameter: Blood Urea Nitrogen (BUN), Potassium, Sodium, Chloridion, Phosphorus, Calcium and Fasting Blood Glucose
Millimoles per literTenofovir Disoproxil Fumarate 300 mg
Week 48, BUN, n=191-0.046 ± 1.1067
Week 96, BUN, n=1880.000 ± 1.1875
Week 144, BUN, n=1840.037 ± 1.0892
Week 192, BUN, n=1780.143 ± 1.1234
Week 240, BUN, n=1550.131 ± 1.1358
Week 48, Potassium, n=191-0.001 ± 0.3703
Week 96, Potassium, n=1860.002 ± 0.3230
Week 144, Potassium, n=184-0.039 ± 0.3871
Week 192, Potassium, n=1780.015 ± 0.4223
Week 240, Potassium, n=158-0.013 ± 0.3946
Week 48, Sodium, n=1910.21 ± 3.495
Week 96, Sodium, n=186-0.02 ± 3.121
Week 144, Sodium, n=1840.35 ± 2.730
Week 192, Sodium, n=1780.38 ± 2.998
Week 240, Sodium, n=158-0.13 ± 2.707
Week 48, Chloridion, n=191-0.13 ± 3.600
Week 96, Chloridion, n=1860.40 ± 3.535
Week 144, Chloridion, n=1830.35 ± 3.492
Week 192, Chloridion, n=1780.77 ± 3.142
Week 240, Chloridion, n=1580.49 ± 3.364
Week 48, Phosphorus, n=190-0.044 ± 0.1724
Week 96, Phosphorus, n=187-0.038 ± 0.1632
Week 144, Phosphorus, n=184-0.037 ± 0.1955
Week 192, Phosphorus, n=175-0.059 ± 0.1876
Week 240, Phosphorus, n=159-0.042 ± 0.2009
Week 48, Calcium, n=190-0.023 ± 0.1513
Week 96, Calcium, n=187-0.006 ± 0.1652
Week 144, Calcium, n=184-0.022 ± 0.1605
Week 192, Calcium, n=178-0.004 ± 0.1470
Week 240, Calcium, n=158-0.006 ± 0.1558
Week 48, Fasting Blood Glucose, n=191-0.162 ± 0.7154
Week 96, Fasting Blood Glucose, n=188-0.109 ± 0.7139
Week 144, Fasting Blood Glucose, n=185-0.094 ± 0.8979
Week 192, Fasting Blood Glucose, n=177-0.052 ± 0.7548
Week 240, Fasting Blood Glucose, n=1580.052 ± 1.2197
SecondaryChange From Baseline in Chemistry Parameters: Creatinine Clearance Rate

Blood samples were collected to analyze the chemistry parameters: creatinine clearance rate. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

Time frame:
Baseline (Day 0) and at Week 48, Week 96, Week 144, Week 192 and Week 240
Reported as:
Mean · Milliliter per minute (mL/min)
Change From Baseline in Chemistry Parameters: Creatinine Clearance Rate
Milliliter per minute (mL/min)Tenofovir Disoproxil Fumarate 300 mg
Week 48, n=190-3.064 ± 11.5995
Week 96, n=188-4.214 ± 12.7883
Week 144, n=184-4.324 ± 15.3937
Week 192, n=177-6.599 ± 13.8858
Week 240, n=155-6.658 ± 16.5351
SecondaryChange From Baseline in Chemistry Parameters: Estimated Glomerular Filtration Rate (eGFR)

Blood samples were collected to analyze the chemistry parameters: eGFR. Day 0 was considered as Baseline. Change from Baseline was calculated by subtracting Baseline value from the specified time point value.

Time frame:
Baseline (Day 0) and at Week 48, Week 96, Week 144, Week 192 and Week 240
Reported as:
Mean · mL/minute per 1.73 square meter
Change From Baseline in Chemistry Parameters: Estimated Glomerular Filtration Rate (eGFR)
mL/minute per 1.73 square meterTenofovir Disoproxil Fumarate 300 mg
Week 48, n=191-0.86 ± 6.581
Week 96, n=188-0.87 ± 7.078
Week 144, n=185-0.68 ± 8.368
Week 192, n=180-1.06 ± 8.442
Week 240, n=161-1.42 ± 9.609

Adverse events

Collected over All cause mortality, non-serious TEAEs and serious TEAEs were collected up to 240 weeks from the start of the treatment.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tenofovir Disoproxil Fumarate 300 mg2/195 (1%)34/195 (17.4%)129/195 (66.2%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventTenofovir Disoproxil Fumarate 300 mg
Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)13/195
CholelithiasisHepatobiliary disorders2/195
Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/195
Ovarian germ cell teratomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/195
Foot fractureInjury, poisoning and procedural complications1/195
Lower limb fractureInjury, poisoning and procedural complications1/195
Post procedural bile leakInjury, poisoning and procedural complications1/195
Radius fractureInjury, poisoning and procedural complications1/195
Spinal compression fractureInjury, poisoning and procedural complications1/195
Tibia fractureInjury, poisoning and procedural complications1/195
Most frequent other events
Showing 10 of 133
Most frequent other events
EventTenofovir Disoproxil Fumarate 300 mg
Upper respiratory tract infectionInfections and infestations36/195
HypophosphataemiaMetabolism and nutrition disorders15/195
Urinary tract infectionInfections and infestations11/195
Blood creatine phosphokinase increasedInvestigations9/195
AnaemiaBlood and lymphatic system disorders9/195
HypocalcaemiaMetabolism and nutrition disorders7/195
AscitesGastrointestinal disorders6/195
ToothacheGastrointestinal disorders5/195
CholelithiasisHepatobiliary disorders5/195
HypertensionVascular disorders5/195

Baseline characteristics

Baseline characteristics is presented for modified Intent-to-treat (mITT) Population which consisted of all participants who received at least one dose of study medication. 2 participants did not receive TDF treatment thus excluded from mITT Population

Age, Continuous
Age, Continuous(Years)Tenofovir Disoproxil Fumarate 300 mg
Mean42.3 ± 9.80
Sex: Female, Male
Sex: Female, Male(Participants)Tenofovir Disoproxil Fumarate 300 mg
Female47
Male148
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Tenofovir Disoproxil Fumarate 300 mg
Asian195
08

Study locations

19 sites
  • GSK Investigational Site
    Guangzhou, Guangdong 510060, China
  • GSK Investigational Site
    Wuhan, Hubei 430022, China
  • GSK Investigational Site
    Nanjing, Jiangsu 210002, China
  • GSK Investigational Site
    Nanjing, Jiangsu 210003, China
  • GSK Investigational Site
    Changchun, Jilin 130000, China
  • GSK Investigational Site
    Xian, Shanxi 710038, China
  • GSK Investigational Site
    Chengdu, Sichuan 610041, China
  • GSK Investigational Site
    Beijing, 100044, China
  • GSK Investigational Site
    Beijing, 100050, China
  • GSK Investigational Site
    Beijing, 100069, China
  • GSK Investigational Site
    Chongqing, 400038, China
  • GSK Investigational Site
    Hangzhou, 310000, China
  • GSK Investigational Site
    Jinan, 250021, China
  • GSK Investigational Site
    Shanghai, 200025, China
  • GSK Investigational Site
    Shanghai, 200040, China
  • GSK Investigational Site
    Shanghai, 201508, China
  • GSK Investigational Site
    Taiyuan, 030001, China
  • GSK Investigational Site
    Xi'an, 710061, China
  • GSK Investigational Site
    Zhengzhou, 450000, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2015 to primary completion in Dec 2020, 68 months.

Results were first posted in Feb 2022, 1 year 2 months after primary completion.

Of 63 phase 4 interventional studies under Hepatitis B, Chronic, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 64. This study's 68 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2014
First posted
Aug 25, 2014
StartActual
Mar 25, 2015
Primary completionActual
Dec 4, 2020
CompletionActual
Dec 4, 2020
Results first posted
Feb 14, 2022
Last update
Feb 14, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 14, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02224456
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 25, 2014
Start date
Mar 25, 2015
Primary completion
Dec 4, 2020
Completion
Dec 4, 2020
Results posted
Feb 14, 2022
Last update
Feb 14, 2022

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tenofovir

Start the discussion